Pasireotide
Other / unclassified targets IGF1, IGF1R, SSTR1, SSTR2, SSTR3, SSTR5 via inhibition / activation
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Signifor | — | 2012-04-24 | europa.eu ↗ |
Trials 73 · started per year
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07312643 Comparator | Dec 2025 → Feb 2026 | — | RECORDATI GROUP | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01670110 Comparator | Aug 2012 → Sep 2018 | autosomal dominant polycystic kidney disease, autosomal dominant polycystic liver disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 2 | NCT02622906 Comparator | Mar 2012 | angiodysplasia of intestine | Robert Benamouzig | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01620138 Comparator | Mar 2010 → Jun 2012 | non-functioning pituitary adenoma, prolactin-producing pituitary gland adenoma | Federal University of Rio de Janeiro | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00690430 Comparator | Apr 2008 → Apr 2012 | carcinoid syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT02775227 Comparator | May 2016 → Jan 2019 overdue | pancreatic neoplasm | Helsinki University Central Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02060383 Background | May 2014 → Feb 2018 | Cushing disease due to pituitary adenoma, acromegaly | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 24 cited values
Every value below carries the sentence it was read from. 88 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pasireotide | “Since the importance of the IGF-signaling in PC is not only indicated by preclinical results but also by clinical efficacy of somatostatin analogs, further clinical research...” NCT01646684 ↗69“Our objective was to evaluate the short-term efficacy of the novel multireceptor ligand somatostatin analog pasireotide in patients with de novo, persistent, or recurrent...” PMID 18957506 ↗ Oct 2008 “Subcutaneous (s.c.) Pasireotide in Subjects With Varying Degrees of Renal Impairment Compared to a Matched Control Group of Healthy Volunteers” NCT01578928 ↗ “Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate).” NCT06456359 ↗ “SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days.” NCT01625520 ↗ “Pasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind” PMID 26126727 ↗ Jul 2015 |
| Known as | PAS-LAR | “To assess the efficacy and safety of pasireotide long-acting release (PAS-LAR) alone or in combination with pegvisomant” PMID 29155991 ↗ Feb 2018 |
| Known as | Pasireotida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | Pasireotide (as diaspartate) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | Pasireotide Diaspartate | “Drug: Pasireotide Diaspartate” NCT05928390 ↗ |
| Known as | Pasireotide embonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | Pasireotide LAR | “Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom...” NCT02749227 ↗5“Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).” NCT01374451 ↗ “Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.” NCT00958841 ↗ “Pasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind” PMID 26126727 ↗ Jul 2015 “Pasireotide LAR (SOM230)” NCT01670110 ↗ “Drug: Pasireotide LAR” NCT01283542 ↗ |
| Known as | Pasireotide long-acting release | “Pasireotide long-acting release, with its broader binding profile and higher affinity to known somatostatin receptors, has potential for greater efficacy.” PMID 32843370 ↗ Aug 2020 |
| Known as | pasireotide pamoate | “Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate).” NCT06456359 ↗ |
| Known as | Signifor | “Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate).” NCT06456359 ↗ |
| Known as | Signifor lar | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | Signifor lar kit | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | SOM-230 | “The purpose of this study is to help us learn more about how to lower the patient's risk of the most common complications after their pancreas operation. After tumors are...” NCT00994110 ↗21“A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in...” NCT00434148 ↗ “An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (som230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients...” NCT01617733 ↗ “Pasireotide (SOM230, SIGNIFOR®) is currently indicated for the treatment of patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.” NCT02713776 ↗ “Pasireotide (SOM230), a multireceptor-targeted somatostatin analogue, has exhibited favorable safety/tolerability in several clinical studies.” PMID 24800725 ↗ May 2014 “Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog with affinity for somatostatin receptor subtypes sst(1-3) and sst(5).” PMID 20410233 ↗ Apr 2010 “Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.” PMID 22282526 ↗ Jan 2012 “A Phase II Trial of SOM230(PasireotideLAR) and Topotecan in Patients With Relapsed or Refractory Small Cell Lung Cancer” NCT01417806 ↗ “Pasireotide (SOM230) s.c.Followed by Pasireotide LAR” NCT01652547 ↗ “The study evaluated SOM230 vs Placebo” NCT02619617 ↗ “Pasireotide is also called SOM-230.” NCT01252251 ↗ “Pasireotide LAR (SOM230)” NCT01670110 ↗ “SOM 230 / Pasireotide” NCT01372644 ↗ “SOM 230 / Pasireotide” NCT01372618 ↗ |
| Known as | SOM-230 PAMOATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3349607 ↗ |
| Known as | SOM230 LAR | “SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma” NCT01329289 ↗2“Pasireotide LAR (SOM230 LAR) is a cyclohexapeptide engineered to bind” PMID 26126727 ↗ Jul 2015 |
| Known as | SOM230C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00859040 ↗ |
| Action | Activate | “Somatostatin receptor 3 agonist” CHEMBL3349607 ↗1“Somatostatin receptor 2 agonist” CHEMBL3349607 ↗ |
| Action | Inhibit | “Serum cortisol levels and plasma ACTH levels were also reduced.” PMID 18957506 ↗ Oct 2008 |
| Modality | Other / unclassified | “Pasireotide (SOM230) is a novel multireceptor ligand somatostatin analog” PMID 20410233 ↗ Apr 2010 |
| Route | Subcutaneous | “each patient received pasireotide 200, 400, and 600 microg s.c. twice daily” PMID 20410233 ↗ Apr 2010 |
| Target | SSTR1 | “Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5).” PMID 25376618 ↗ Nov 2014 |
| Target | SSTR2 | “Somatostatin receptor 2 agonist” CHEMBL3349607 ↗ |
| Target | SSTR3 | “Somatostatin receptor 3 agonist” CHEMBL3349607 ↗ |
| Target | SSTR5 | “Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5).” PMID 25376618 ↗ Nov 2014 |